BIOATLA INC
BCABNASDAQ🏆 #3714 by market capEarnings Nov 11US Equity
$3.49▲ $0.04 (+1.16%)
Live1h—
24h▲ 1.2%
7d▲ 2.9%
14d▲ 0.9%
30d▼ 6.7%
1y▼ 80.1%
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
-81.8%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
3.0x
Fair
Otter Score
42
Weak
Trading Snapshot
- Day Range
- $3.45 – $3.53
- 52-Week Range
- $3.12 – $71.50
- Volume
- $2.59B
- Avg Volume
- $3.22B
- Shares Outstanding
- 1.7M
- Next Earnings
- Sep 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $463,021
- P/E Ratio
- —
- P/S Ratio
- 3.0x
- EPS (TTM)
- $-41.82
- Dividend Yield
- —
Why Investors Own BCAB
- ✓High-growth profile — revenue up -7.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 76% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$2M▼ −10.4% YoY
Gross Margin (TTM)
75.7%▲ +3.7% YoY
Operating Income (TTM)
$368,004▼ −10.4% YoY
Free Cash Flow (TTM)
$224,003▼ −10.4% YoY
About BIOATLA INC
A company profile for BIOATLA INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
42/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy3
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026
